Dong-A St (KO:170900) — Market Cap & Net Worth
Market Cap & Net Worth: Dong-A St (170900)
Dong-A St (KO:170900) has a market capitalization of $235.28 Million (₩347.18 Billion) as of September 16, 2026. Listed on the KO stock exchange, this Korea-based company holds position #15992 globally and #563 in its home market, demonstrating a -1.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dong-A St's stock price ₩36000.00 by its total outstanding shares 9643760 (9.64 Million). Also see Dong-A St assets under control for a full breakdown of the balance sheet.
Dong-A St Market Cap History: 2015 to 2026
Dong-A St's market capitalization history from 2015 to 2026. Data shows change from $855.82 Million to $235.28 Million (-9.43% CAGR). Also see 170900 cash generation efficiency for how efficiently the company converts equity into cash flow.
Dong-A St Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dong-A St's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Dong-A St for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Dong-A St's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $617.60 Million | $560.54 Billion | $10.63 Billion | 0.00x | 0.06x |
| 2017 | $586.04 Million | $555.03 Billion | -$5.40 Billion | 0.00x | N/A |
| 2018 | $620.67 Million | $567.43 Billion | $8.01 Billion | 0.00x | 0.08x |
| 2019 | $712.89 Million | $612.31 Billion | $70.91 Billion | 0.00x | 0.01x |
| 2020 | $537.03 Million | $586.73 Billion | $27.10 Billion | 0.00x | 0.02x |
| 2021 | $440.06 Million | $593.23 Billion | $12.82 Billion | 0.00x | 0.03x |
| 2022 | $385.50 Million | $635.39 Billion | $13.55 Billion | 0.00x | 0.03x |
| 2023 | $451.60 Million | $663.98 Billion | $11.12 Billion | 0.00x | 0.04x |
| 2024 | $384.28 Million | $697.87 Billion | -$1.22 Billion | 0.00x | N/A |
| 2025 | $343.11 Million | $808.78 Billion | -$28.59 Billion | 0.00x | N/A |
Competitor Companies of 170900 by Market Capitalization
Companies near Dong-A St in the global market cap rankings as of September 16, 2026. Review Dong-A St (170900) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Dong-A St by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Dong-A St Historical Marketcap From 2015 to 2026
Between 2015 and today, Dong-A St's market cap moved from $855.82 Million to $ 235.28 Million, with a yearly change of -9.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩235.28 Million | -31.43% |
| 2025 | ₩343.11 Million | -10.71% |
| 2024 | ₩384.28 Million | -14.91% |
| 2023 | ₩451.60 Million | +17.15% |
| 2022 | ₩385.50 Million | -12.40% |
| 2021 | ₩440.06 Million | -18.06% |
| 2020 | ₩537.03 Million | -24.67% |
| 2019 | ₩712.89 Million | +14.86% |
| 2018 | ₩620.67 Million | +5.91% |
| 2017 | ₩586.04 Million | -5.11% |
| 2016 | ₩617.60 Million | -27.84% |
| 2015 | ₩855.82 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Dong-A St was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $235.28 Million USD |
| MoneyControl | $235.28 Million USD |
| MarketWatch | $235.28 Million USD |
| marketcap.company | $235.28 Million USD |
| Reuters | $235.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more